Back to top
more

Vericel (VCEL)

(Delayed Data from NSDQ)

$47.83 USD

47.83
345,262

-0.05 (-0.10%)

Updated May 3, 2024 04:00 PM ET

After-Market: $47.79 -0.04 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is a Beat in the Cards for CVS Health (CVS) in Q4 Earnings?

Through November and December, the resurgence of new COVID-19 cases might have resulted in more COVID-19 tests conducts by CVS Health (CVS).

Higher Testing Volume to Aid LabCorp's (LH) Q4 Earnings

LabCorp's (LH) fourth-quarter base-business performance is expected to have registered slower recovery rate compared to the third quarter.

Vericel Corporation (VCEL) Moves to Strong Buy: Rationale Behind the Upgrade

Vericel Corporation (VCEL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Vericel, Intuit, Mosaic, Ally Financial and D.R. Horton highlighted as Zacks Bull and Bear of the Day

Vericel, Intuit, Mosaic, Ally Financial and D.R. Horton highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bull of the Day: Vericel (VCEL)

Restoring cartilage in sports medicine and rebuilding skin after severe burns gave this small-cap big upside

Zacks Market Edge Highlights: Vericel, Tesla, Chewy, Alibaba and Facebook

Zacks Market Edge Highlights: Vericel, Tesla, Chewy, Alibaba and Facebook

Tracey Ryniec headshot

Should You Sell Your Big Winner Stocks?

One of the most difficult parts of investing is knowing when to sell your stocks. After a red hot 2020, what should you do?

Tracey Ryniec headshot

Stock Investors: What's the Next Hot Industry?

Technology won't always be on top. There's a bunch of budding industries that could prove to be winners over the next 5 years.

Vericel Corp, Nikola Corp, Lowe's, Dollar General and Best Buy highlighted as Zacks Bull and Bear of the Day

Vericel Corp, Nikola Corp, Lowe's, Dollar General and Best Buy highlighted as Zacks Bull and Bear of the Day

Kevin Cook headshot

Bull of the Day: Vericel (VCEL)

Restoring cartilage in sports medicine and rebuilding skin after severe burns gives this small-cap big upside

Vericel Corp (VCEL) Sees Hammer Chart Pattern: Time to Buy?

Vericel Corp (VCEL) has been struggling lately, but the selling pressure may be coming to an end soon.

Alkermes (ALKS) Beats on Q3 Earnings & Sales, Lifts Guidance

Alkermes (ALKS) beats earnings and sales estimates in the third quarter of 2020. The company also raises 2020 guidance.

Alexion (ALXN) Beats on Q3 Earnings & Sales, Ups '20 Guidance

Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.

Dr. Reddy's (RDY) Q2 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline year over year while sales increase in second-quarter fiscal 2021.

Do Options Traders Know Something About Vericel (VCEL) Stock We Don't?

Investors need to pay close attention to Vericel (VCEL) stock based on the movements in the options market lately.

Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories

Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories

Dump These 4 Toxic Stocks or Sell Short for Timely Profits

Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.

Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems

Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems

Dump These 5 Toxic Stocks Right Away

Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.

Assertio (ASRT) to Report Q4 Earnings: What's in Store?

During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.

AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?

During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.

Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?

We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.

BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?

Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.

Is a Beat in Store for Perrigo (PRGO) This Earnings Season?

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be-reported quarter.

Should You Buy Vericel (VCEL) Ahead of Earnings?

Vericel (VCEL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.